Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.

Journal: Cell

Published: 2020-08-05

DOI: 10.1016/j.cell.2020.08.002

Affiliations: 26

Authors: 45

Go to article
Institutions Share
Tumour Immunology and Anti-Cancer Immunotherapy Unit, France 0.16
Cochin Hospital, France 0.16
Laboratory for Immunomonitoring in Oncology (LIO), France 0.10
Institut Cochin, France 0.10
Department of Medical Oncology, IGR, France 0.07
Institute Gustave-Roussy (IGR), France 0.05
Hôtel-Dieu de Paris, France 0.04
Faculty of Medicine, Sorbonne University, France 0.03
Department of Immunology, WIS, Israel 0.03
Département de Biologie et Pathologie Médicales, IGR, France 0.03
Ecophysiologie et Génomique Fonctionnelle de la Vigne (EGFV), France 0.03
Predictive Biomarkers and Novel Therapeutic Strategies in Oncology, France 0.03
Singapore Immunology Network (SIgN), A*STAR, Singapore 0.03
Faculté de Médicine, Université Paris Saclay, France 0.02
Centre for Research in Epidemiology and Population Health (CESP), France 0.02
Department of Drug Development (DITEP), IGR, France 0.01
Center of Bioinformatics, Biostatistics and Integrative Biology (C3BI), France 0.01
Département d’Hématologie, IGR, France 0.01
National Clinical Research Center for Infectious Diseases at Shenzhen Third People's Hospital, SUSTech, China 0.01
School of Medicine, SUSTech, China 0.01
Center of Clinical Investigations in Biotherapies of Cancer (CICBT), France 0.01
Shanghai Institute of Immunology (SII), SJTU, China 0.01
Duke-NUS Graduate Medical School Singapore, Singapore 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER